Oktoobar 31, 2023, Maamulka Cuntada iyo Dawooyinka ayaa oggolaaday pembrolizumab (Keytruda, Merck) in lagu isticmaalo gemcitabine iyo cisplatin si loogu daweeyo kansarka biliary tract carcinoma (BTC) kaas oo faafay ama ku horumaray gudaha laakiin aan laga saari karin.
Waxtarka waxaa lagu qiimeeyay daraasad la yiraahdo KEYNOTE-966 (NCT04003636), taas oo ahayd xarun badan, randomized, double-indhole, tijaabo placebo-control oo ku lug leh 1069 bukaan oo leh BTC heer sare ah oo aan la dabooli karin ama metastatic BTC kuwaas oo aan hore loo marin daaweynta nidaamsan ee jirrooyinka sare. . Bukaannada ayaa si aan kala sooc lahayn loogu qoondeeyay inay helaan midkood pembrolizumab oo ay weheliso gemcitabine iyo cisplatin 3 toddobaad kasta, ama placebo oo ay weheliso gemcitabine iyo cisplatin isla jadwal isku mid ah. Daawadu way sii socotay ilaa waxyeelooyinka aan loo dulqaadan karin ama horumarka cudurka. Cisplatin waxaa la siiyay ilaa 8 wareegyo, halka gemcitabine la sii waday iyadoo lagu saleynayo xukunka dhakhtarka. Maamulka Pembrolizumab ama placebo waa la joogteeyey ilaa uu cudurku ka sii socdo, suntan aan loo dulqaadan karin, ama muddada ugu badan ee 2 sano ah.
Meesha ugu dambaysa ee waxtarka leh waxay ahayd badbaadada guud (OS). Pembrolizumab oo lagu daray kiimoterabiga ayaa muujiyay koror la taaban karo ee badbaadada guud marka la barbar dhigo placebo oo lagu daray kiimoterabi, oo leh saamiga khatarta ah 0.83 (95% CI: 0.72, 0.95); hal dhinac p-qiimaha=0.0034. Badbaadinta guud ee dhexdhexaadka ah (OS) waxay ahayd bilaha 12.7 oo leh 95% kalsoonida kalsoonida (CI) ee 11.5 ilaa 13.6 hal koox, iyo 10.9 bilood oo leh 95% CI ee 9.9 ilaa 11.6 kooxda kale.
Joojinta pembrolizumab dhacdooyinka xun dartood waxay ku dhacday 55% bukaannada. Tirada neutrophils hooseeya, tirada platelet oo hooseeya, dhiig-yarida, tirada unugyada dhiigga cad oo hooseeya, qandho, daal, cholangitis, kor u kaca ALT iyo AST, iyo xannibaadda biliary ayaa ah qaar ka mid ah dhibaatooyinka soo raaca ama dhibaatooyinka shaybaadhka ee dhaca inta badan (≥2%) daawaynta waxay ahayd in la joojiyo.
Qiyaasta la soo jeediyay ee pembrolizumab waa 200 mg 3 toddobaad kasta ama 400 mg 6dii toddobaadba mar ilaa cudurku ka sii socdo ama sunta aan loo dulqaadan karin. Maamul pembrolizumab ka hor daaweynta kemotherabi haddii labadaba la bixiyo isku maalin.
Kansarka
Lutetium Lu 177 dotatate waxa ansixisay USFDA bukaanada carruurta 12 sano iyo ka weyn ee GEP-NETS
Lutetium Lu 177 dotatate, oo ah daawayn hor leh, ayaa dhawaan ogolaansho ka heshay Maamulka Cunnada iyo Dawooyinka ee Maraykanka (FDA) ee bukaanada carruurta, taas oo calaamad u ah guul muhiim ah oo ku saabsan kansarka carruurta. Oggolaanshahani waxa uu u taagan yahay iftiin rajo u ah carruurta la dagaallamaysa burooyinka neuroendocrine (NETs), oo ah nooc naadir ah laakiin adag oo kansar ah kaas oo inta badan caddeeya u adkaysiga daaweynta caadiga ah.
Alysha Mendossa
Waxaa laga yaabaa 11, 2024
